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Abstract The common theme of this introductory article
and the minireviews that follow in this special issue is the
concept of microenvironments within tissues and surround-
ing cells that would be ideal signaling venues for a
biologically active purinergic ligand. Collectively, the
editors/authors and the other contributing authors agree
that nucleotides and nucleosides would be most potent
within a confined system. A talented cadre of purinergics
has been solicited to discuss purinergic signaling in his or
her favorite microenvironment within a given organ or
tissue. We are gratified by the large number of original
articles that also have successfully navigated the peer
review process and are part of this special issue. These
concepts are not simply purinergic, but the idea of maximal
potency in a tissue microenvironment and surrounding
specialized cells within a tissue pertains to any autacoid or
paracrine agonist.
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Abbreviations
ATP adenosine 5′ triphosphate
P2X or P2XR P2X purinergic receptor channel
P2Y P2Y G-protein-coupled receptor
ADP adenosine diphosphate
AMP adenosine monophosphate
CF cystic fibrosis
ASL airway surface liquid
ASF airway surface fluid
PCL periciliary liquid layer
ELF epithelial lining fluid
Ca
2+ Calcium
Na
+ Sodium
Introduction
Adenosine 5′ triphosphate (ATP) and adenosine are
extracellular autocrine and paracrine signaling molecules.
The most potent effects of ATP and adenosine are likely
limited to extracellular microenvironments within tissues or
immediately surrounding a cell or group of cells. These
extracellular microenvironments may have a limited area of
diffusion, have a small volume, have an ideal ionic
composition and pH, represent an unstirred layer near a
membrane surface, represent a trapped interstitium, or any
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Birmingham, AL 35203, USAand all of the above. If P1 or P2 nucleotide receptors are
present on a membrane that is exposed to released
nucleotide or nucleoside in this microenvironment, these
ligands can engage P1 G-protein-coupled receptors, P2Y G-
protein-coupled receptors or P2X receptor channels and
affect the function of the cell on which it binds. Besides
ATP and adenosine, other forms of nucleotides and
nucleosides may also be active extracellular signaling
ligands and may have unappreciated receptors. Inosine,
thymidine, and even cyclic nucleotides are released by and
may have effects on mammalian cells. The self-aggregation
signal for the slime mold Dictyostelium discoideum,i s
cyclic adenosine monophosphate (AMP). Receptors for
cyclic nucleotides have only been defined until now in the
lower biological systems. Receptors for cyclic nucleotides
as well as inosine or thymidine may also exist on
mammalian cells and receive this autocrine signal within a
microenvironment.
Ideal microenvironments for purinergic signaling
For simplicity, we focus on ATP and its metabolites. Many
different microenvironments have been studied in great
detail and are described and included below. One classical
microenvironment that has emerged in importance in the
cystic fibrosis (CF) research community is in an open
system but is a stirred liquid layer trapped between the
luminal membrane of the airways epithelium and the
humidified air that fills the lung and airways. The airway
surface liquid [ASL, also termed airway surface fluid
(ASF), the periciliary liquid layer (PCL), and the epithelial
lining fluid (ELF)] bathes motile respiratory cilia [1–4]. The
humidified air above this layer and the ciliated apical or
luminal membrane beneath this layer help close this
microenvironment. Submucosal gland secretions may also
contribute importantly to its composition. Ric Boucher and
his many coworkers have presented many recent seminal
contributions on the purinergic signaling that may occur in
the ASL—among its many other properties [3, 4]. There are
similar microenvironments of this type that are also
discussed in review articles within this special issue. Daniel
Marcus and colleagues and Claire Mitchell and coworkers
discuss liquid microenvironments in the ear and the eye,
respectively [5, 6], which provide a medium for purinergic
signaling.
A second classical microenvironment is a closed and
open system that is compromised of a secretory gland or
acinus and a collecting or draining duct. Iva Novak and
colleagues have done seminal work in the pancreas in this
regard [7, 8]. Geoff Burnstock has often discussed the rich
purinergic signaling that occurs in tubes or ducts [9, 10]. In
this microenvironment, glandular and acinar secretions may
convey the purinergic ligands so that they may act in an
autocrine manner at the acinus or in a paracrine manner
within the duct. However, it is an open system in that these
secretions eventually exit this tissue environment. The
airway submucosal gland beneath the airway surface
epithelium may be one such example that conveys
purinergic signals to the surface where they may drive
ciliary beat and other functions. The pancreatic acinus and
duct, the sweat gland and duct, and the bile secretory
apparatus and the bile duct are all important examples.
A third microenvironment is a closed system in which
the purinergic ligands concentrate within a small volume
and within a tissue. Here, the purinergic ligands bind and
activate receptors until they are either degraded or
reabsorbed by the cells that secreted them or by neighbor-
ing cells. The endolymph of the ear and the humors of the
eye are ideal examples of such closed systems [11, 12].
Marcus and colleagues and Mitchell and coworkers discuss
these systems in minireviews alluded to above [5, 6].
Original articles and reviews in this issue and future issues
of Purinergic Signalling speak to such systems in pancre-
atic islets and in the many renal tubules that comprise the
nephron of the kidney [13]. In polycystic kidney and liver
disease, tubules remodel into abnormal fluid-filled cysts.
Multiple laboratories have argued that the fluid-filled lumen
of the encapsulated cyst is a rich yet pathophysiological
microenvironment for purinergic signaling [14–20]. The
minireviews that follow this introductory article focus on
specific microenvironments, cells and tissues that create
and/or come in contact with such microenvironments, and
all possible modes of purinergic signaling within these
microenvironments.
An ideal microenvironment paradigm for extracellular
purinergic signaling: the synapse
Many reviews in the past [21–23] and in the initial issues of
this journal have documented well the roles of the P2X
receptor channel at the synapse between neurons. Indeed,
P2Y receptors may play roles in synaptic transmission as
well. This is analogous to the interplay between cholinergic
and muscarinic receptor systems in cholinergic neurons and
synapses in many different nuclei and regions of the brain.
In fact, the purinergic field was born from the classical
studies of extracellular ATP on the heart by Drury and
Szent-Gyorgyi [24], in the definition of purinergic nerves in
the enteric nervous system by Burnstock and colleagues
[25], and on the release and effects of purinergic ligands
such as ATP on skeletal muscle contractility by Tom
Forrester (see “Historical Perspective” by T. Forrester in
this issue, [26]). The authors lead this series of minireviews
with the idea that the synapse is the ideal and, perhaps, the
90 Purinergic Signalling (2008) 4:89–92first or founding microenvironment for autocrine and
paracrine purinergic biology.
The synapse is designed to have a limited diffusion
distance between pre- and postsynaptic membranes where
the principal ligand or neurotransmitter is reabsorbed by the
presynapse or degraded in the synapse. For the sake of
simplicity, our narrative here focused first on a purinergic
synapse where released ATP acts as the principal ligand to
evoke an action potential in the postsynaptic membrane.
ATP as the lead neurotransmitter is released in response to
an action potential in the presynaptic bulb that opens
voltage-dependent calcium (Ca
2+) channels. This voltage-
dependent Ca
2+ entry signal triggers the fusion or exocy-
tosis of ATP-filled synaptic vesicles so that labile ATP is
secreted into the synaptic cleft. Extracellular ATP-gated
P2X receptor channels on the postsynaptic membrane have
a large extracellular domain poised to bind that ATP
immediately upon release within a synaptic microenviron-
ment where there is a short diffusion distance and a small
volume. In other words, the synapse is an ideal microen-
vironment for paracrine purinergic signaling. In this
paradigm, the ATP is likely degraded to adenosine
diphosphate (ADP), 5′ AMP and adenosine, where adeno-
sine may be recycled back into the presynapse by
nucleoside transporters only to be a substrate to synthesize
new ATP for metabolism or neurotransmission.
Several additional functions for P2X receptor channels
have been proposed in neurotransmission driven by other
neurotransmitters. For example, at the glutamate synapse, it
is well known that ATP is released as a cotransmitter. A
classical example of this is the hair-cell sound transduction
process, where glutamate and ATP are coreleased to
stimulate auditory afferents [11]. How may ATP affect
responses to glutamate at glutamate, N-methyl-D-aspartate
(NMDA), and kainate receptor channels in the postsynaptic
membrane and/or at the presynapse in terms of release of
ligand? Many possible cotransmitter effects have also been
entertained and studied. We do not wish to debate the
relative roles of P2X receptor channels in neurotransmis-
sion. The possible explanations of ATP effects at an
excitatory glutamatergic synapse are given in simplistic
terms. We only wish to show the synapse as a lead
microenvironment to illustrate how and why local ATP
signaling may be important.
First, the presence of a postsynaptic P2X receptor
channel or channels would potentiate the excitation of
glutamate postsynapse. Not only do NMDA, kainate, and
glutamate itself potentiate Ca
2+ and sodium (Na
+) entry as
Ca
2+ permeable nonselective cation channels, but extracel-
lular ATP-gated P2X receptor channels open a separate
pathway for Ca
2+ and Na
+. Flow of Ca
2+ and Na
+ through
parallel pathways driven by these cotransmitters would lead
to a much quicker development of a postsynaptic potential.
Moreover, with Ca
2+ entering with Na
+, it is likely that the
action potential may be more long-lived and possibly more
robust (i.e., having a shoulder or plateau due to Ca
2+ entry
beyond the Na
+-driven spike). Second, ATP could poten-
tiate glutamate release at the presynaptic neuron by
potentiating Ca
2+ entry driven by the preceding action
potential. A more robust Ca
2+ entry would cause more or
secondary glutamate release and would keep the postsyn-
aptic neuron firing. As for acetylcholine, ATP also has G-
protein-coupled receptors, the P2Y receptors, which could
modulate presynaptic and/or postsynaptic neuron function.
Third, could metabolites of ATP limit activation of the
postsynaptic and presynaptic neuron? One does not wish
for the postsynaptic neuron to continue firing ad infinitum.
One must have a limiting or negative feedback signal.
Could this signal be adenosine? Not only does adenosine
need to be recycled back into the neuron as a substrate for
new ATP synthesis, but adenosine may also bind to P1 G-
protein-coupled receptors to have limiting effects or
neuronal function. Of course, ATP release and signaling at
an inhibitory synapse driven by γ-aminobutyric acid
(GABA) or glycine would have different and modulating
effects on inhibitory synapse. We do not discuss or illustrate
these possible mechanisms because that is not the intent of
this introductory minireview. Synaptic purinergic neuro-
transmission has been reviewed by Burnstock and others in
many seminal reviews [9, 10, 21–23].
Conclusions and future directions
The founding concepts of purinergic signaling within
tissues and tissue microenvironments were found in the
heart, the enteric system (later to be duplicated in urinary
bladder afferents, nociceptive neurons at the dorsal root
ganglia of the spinal cord, etc.), and skeletal muscle by
Forrester and coworkers [26]. This special issue of
Purinergic Signalling focusing on the “Physiology of
Nucleotide Release” is dedicated to these and other
pioneers who would not give up the fight. All purinergics
would agree that we owe the purinergic pioneers a great
debt. Through their efforts, establishment of this journal,
and the increasing volume of research in purinergic
signaling, it is now accepted that ATP and its metabolites
have two principal biological roles—as an extracellular
signaling ligand and as an intracellular fuel.
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